RE:$175M USD raise by Avalyn, CEAPRO needs to move on Y-BGCiao wrote: Avalyn raised $175M USD for their work on pulmory fibrosis / interstial lung disease
https://www.avalynpharma.com/avalyn-raises-175-million-in-oversubscribed-series-c-financing-to-advance-inhaled-pulmonary-fibrosis-programs-into-later-stage-clinical-studies/ CEAPRO needs to move forward with their clinical Y-BG study
“Until now, we have had very limited treatment options for fibrotic lung disease since approved medications can only slow down the progression of the disease. We are very encouraged by the results from this study showing that PGX-YBG has the ability of reprogramming macrophages to prevent fibrogenesis in mice. If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University.
“Our initial hypothesis was that PGX-YBG particles could be safely delivered into human lungs. These results provide encouraging confirmation of that hypothesis and bolster our confidence for the continued development toward a potential treatment option for IPF,” stated Gilles Gagnon, President and CEO of Ceapro. “This evidence, along with the latest in-vitro and in-vivo data, provides the validation that PGX-YBG holds significant potential as a therapeutic strategy for a broad spectrum of fibrotic end-point lung diseases such as COVID-19 related lung fibrosis and IPF. With these results now in hand, we are evaluating our pre-planned go/no-go decision for advancement of this program into a Phase 1 clinical trial and expect to provide updates in Q3 of this year.”
https://stockhouse.com/news/press-releases/2023/05/23/ceapro-inc-presents-encouraging-results-from-research-collaboration-study-with
The entire Y-BG initiative could have accelerated to a level where CEAPRO could be raising tens of millions of dollars had Gilles executed on the potential 3 years ago with a sense of urgency (oh yeah, COVID pandemic should have been a motivator given the world was in a state of emergency). Raising funds back then would have been easy or even now if they moved Y-BG to a clinical stage would circumvent the sham idea that CZO needs funds from the AEZS merger.
PGX is a gold mine, and Y-BG as an inhalable therapeutic is a gem that Gilles has slow walked over the past few years, and now he wants to gift it in a merger. With CZO at .20, it has a market cap of $16M or $5M ex cash....that's the value of the base business and PGX (Y-BG as an inhalable therapeutic for IPF could be worth hundreds of millions of dollars)
“We are very proud of the work that has been conducted so far and believe we are well-positioned to offer an additional tool in the fight against COVID-19, which is having devastating effects worldwide. With the expected completion of the third and fourth goals related to tolerability, safety and efficacy studies with both nave and pre-clinical animal models as early as mid-October, our teams are positioning us to be ahead of schedule. Hoping for favorable pre-clinical results, preparations of a Phase 1/2 clinical trial protocol will be commenced immediately and planned to be submitted to Health Authorities during Q4 2020. Given that yeast beta-glucan is already approved as a pharmaceutical additive, we expect to quickly develop PGX-YBG as a fast-acting inhalable stand-alone therapeutic and/or delivery system to treat severe inflammation observed in COVID-19 patients and other fibrotic end-point disease in the lung,” commented Gilles Gagnon
From the Q3 report 2 weeks before the sham merger announcement;
...we remain in a solid financial position and will continue to focus our efforts on the development of new products and technologies using cash in hand while continuing to assess different market initiatives to grow our base and create new business with new products and customers,” concluded Mr. Gagnon